

## CORRECTION

### Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

In the article “Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study” by P. O’Connor et al.,<sup>1</sup> there are errors in table 3 and figure 2. In the corrected portion of table 3, the layout of the data for “Patients with  $\geq 1$  relapse” in the teriflunomide 14 mg/14 mg and 7 mg/7 mg columns has been correctly adjusted and shifted down one row. The left panel of figure 2A shows both unconfirmed and confirmed relapses, while the right panel shows confirmed relapses only. In the left panel of figure 2B, the mean ( $\pm$ SD) values should read as follows: 14 mg/14 mg, 0.12 (0.06); 7 mg/7 mg, 0.21 (0.06); placebo/14 mg, 0.24 (0.09); placebo/7 mg, 0 (0.08). In addition, the numbers of patients were transposed between the 7 mg/7 mg group (should be 252 rather than 106 as originally published) and the placebo/14 mg group (should be 106 rather than 252 as originally published). These corrected values required an adjustment to the y axis ( $-0.2$  to  $0.5$ ). These errors do not change the conclusions of the article. See the corrected portion of table 3 and figure 2B below. The authors regret the errors.

## REFERENCE

- O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. *Neurology* 2016;86:920–930.

**Table 3** Clinical and MRI outcomes in the core Teriflunomide Multiple Sclerosis Oral (TEMSO) and extension studies (modified intent-to-treat population)

	Teriflunomide 14 mg/14 mg	Placebo/ teriflunomide 14 mg	Teriflunomide 7 mg/7 mg	Placebo/ teriflunomide 7 mg	Placebo <sup>a</sup>
<b>Clinical outcomes</b>					
<b>Relapse</b>					
No.	251	108	252	129	237
<b>Adjusted ARR</b>					
Core	0.291 <sup>†</sup>	—	0.301 <sup>†</sup>	—	0.440
Extension	0.171	0.177	0.198	0.225	—
Core + extension <sup>b</sup>	0.215 <sup>†</sup>	0.260	0.240 <sup>†</sup>	0.324	—
<b>Patients with <math>\geq 1</math> relapse, n (%)</b>					
Core	96 (38.2)	—	101 (40.1)	—	117 (49.4)
Extension	107 (42.6)	45 (41.7)	105 (41.7)	54 (41.9)	—
Core + extension <sup>b</sup>	141 (56.2)	68 (63.0)	148 (58.7)	81 (62.8)	—

<sup>a</sup>Patients who received placebo in the core study and went on to enter the extension.


<sup>b</sup>Including data from up to 7 years, since the start of the core TEMSO study.

<sup>†</sup> $p < 0.005$  vs placebo (core study).

<sup>†</sup> $p < 0.05$  vs placebo/7 mg (core plus extension), based on  $\chi^2$  test from the estimated rate ratios from the Poisson model.

**Figure 2**

### B. Mean EDSS score



No. of patients	
14 mg/14 mg	251
7 mg/7 mg	252
Placebo/14 mg	106
Placebo/7 mg	128

Author disclosures are available upon request ([journal@neurology.org](mailto:journal@neurology.org)).

# Neurology<sup>®</sup>

## Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

*Neurology* 2016;87;1524  
DOI 10.1212/WNL.0000000000003219

**This information is current as of October 3, 2016**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/87/14/1524.full">http://n.neurology.org/content/87/14/1524.full</a>
<b>References</b>	This article cites 1 articles, 1 of which you can access for free at: <a href="http://n.neurology.org/content/87/14/1524.full#ref-list-1">http://n.neurology.org/content/87/14/1524.full#ref-list-1</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

